Table S1 Sensitivity analysis of hazard ratios for ischaemic heart disease among patients using SGLT2 inhibitors compared to those not using SGLT2 inhibitors.

Table S2. Updated mean values of metabolic risk factors in 6 months, 12 months, 24 months and 36 months after initial of SGLT2 inhibitors compared to other glucose‐lowering drugs.

Table S3. Changes of metabolic risk factors from baseline to 6 months, 12 months, 24 months and 36 months after initial of SGLT2 inhibitors compared to other glucose‐lowering drugs.

Table S4. Subgroup analysis of hazard ratios for ischaemic heart disease among patients using SGLT2 inhibitors compared to those not using SGLT2 inhibitors.

Table S5. Sensitivity analysis of hazard ratios for ischaemic heart diseases among patients using SGLT2 inhibitors compared to those not using SGLT2 inhibitors.

Table S6. Sensitivity analysis of hazard ratios for ischaemic heart diseases among patients using SGLT2 inhibitors compared to those not using SGLT2 inhibitors.

Table S7. Hazard ratios of severe adverse events among patients using SGLT2 inhibitors compared to those not using SGLT2 inhibitors.